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Introduction: The transcription factor activating enhancer binding protein 2 epsilon (AP-2ε) was recently shown to
be expressed during chondrogenesis as well as in articular chondrocytes of humans and mice. Furthermore,
expression of AP-2ε was found to be upregulated in affected cartilage of patients with osteoarthritis (OA). Despite
these findings, adult mice deficient for AP-2ε (Tfap2e−/−) do not exhibit an obviously abnormal cartilaginous phenotype.
We therefore analyzed embryogenesis of Tfap2e−/− mice to elucidate potential transient abnormalities that provide
information on the influence of AP-2ε on skeletal development. In a second part, we aimed to define potential
influences of AP-2ε on articular cartilage function and gene expression, as well as on OA progression, in adult mice.
Methods: Murine embryonic development was accessed via in situ hybridization, measurement of skeletal parameters
and micromass differentiation of mesenchymal cells. To reveal discrepancies in articular cartilage of adult wild-type
(WT) and Tfap2e−/− mice, light and electron microscopy, in vitro culture of cartilage explants, and quantification of
gene expression via real-time PCR were performed. OA was induced via surgical destabilization of the medial
meniscus in both genotypes, and disease progression was monitored on histological and molecular levels.
Results: Only minor differences between WT and embryos deficient for AP-2ε were observed, suggesting that
redundancy mechanisms effectively compensate for the loss of AP-2ε during skeletal development. Surprisingly,
though, we found matrix metalloproteinase 13 (Mmp13), a major mediator of cartilage destruction, to be significantly
upregulated in articular cartilage of adult Tfap2e−/− mice. This finding was further confirmed by increased Mmp13
activity and extracellular matrix degradation in Tfap2e−/− cartilage explants. OA progression was significantly enhanced
in the Tfap2e−/− mice, which provided evidence for in vivo relevance. This finding is most likely attributable to the
increased basal Mmp13 expression level in Tfap2e−/− articular chondrocytes that results in a significantly higher total
Mmp13 expression rate during OA as compared with the WT.
Conclusions: We reveal a novel role of AP-2ε in the regulation of gene expression in articular chondrocytes, as well as
in OA development, through modulation of Mmp13 expression and activity.Introduction
Most components of the vertebrate skeleton are formed
through a complex, multistep process termed endochon-
dral ossification [1]. This process starts during early em-
bryonic development, when mesenchymal cells condense
at specific locations and prefigure future skeletal elements* Correspondence: anja.bosserhoff@fau.de
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stated.[2]. Subsequent differentiation of these cells results in
chondrocytes that synthesize an abundance of extracellu-
lar matrix (ECM) proteins, including collagen type II and
proteoglycans (for example, aggrecan). A premature skel-
etal template is thereby formed, entirely composed of
cartilage [3]. After further differentiation steps, the cells
become hypertrophic, attract blood vessels and ultimately
undergo apoptosis, allowing osteoblasts to infiltrate the
cartilaginous matrix to induce formation of trabecular
bone [4, 5]. Endochondral ossification is completed in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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tissue. However, in all diarthritic joints, a thin layer of per-
manent cartilage tissue remains intact throughout the or-
ganism’s lifetime. This “articular cartilage” acts as a shock
absorber, minimizing peak pressures on the subchondral
bone, and provides a smooth, low-friction gliding surface
for efficient joint movement [6].
Chondrocytes are essential for physiological cartilage
homeostasis. Under normal conditions, they maintain a
constant, albeit low-level, equilibrium of matrix synthesis
and degradation of ECM molecules. The latter is mediated
by proteolytic enzymes such as matrix metalloproteinases
(MMPs) and aggrecanases [7]. According to the prevailing
hypothesis, disruption of this tightly controlled balance is
one of the initial steps in osteoarthritis (OA) development
[7–9]. OA is the most common joint disorder in Western
populations. It is mainly described as an intrinsic, chronic
disease of the articular cartilage (primary OA) [10, 11]. It
is characterized by progressive degradation of the tissue,
accompanied by biochemical and metabolic changes
within the chondrocytes [12]. The exact molecular
mechanisms that are responsible for OA onset are still
poorly understood.
The initiation of OA often occurs on cartilage surface
areas receiving the greatest mechanical forces. Eventu-
ally, chondrocytes begin to upregulate the production of
ECM-degrading enzymes that mediate collagen and pro-
teoglycan depletion. Here, members of the MMP family
are attributed the most important role. MMPs comprise
a group of zinc- and calcium-dependent endopeptidases
that function as collagenases and aggrecanases. Of those,
MMP13 (collagenase 3) is characterized as the central
catabolic mediator that is overexpressed in nearly all cases
of human OA, whereas other MMP variants only irregu-
larly show enhanced expression [13–15]. In addition,
several studies have demonstrated constitutive, albeit low-
grade, expression of MMP13 in healthy human, rat and
pig articular cartilage participating in physiologic ECM
turnover [8, 14, 16, 17].
After a certain period, OA-induced damage of the ar-
ticular cartilage becomes histologically obvious. Begin-
ning with fissures and clefts in the cartilage surface, the
defects quickly expand to the full depth of the tissue.
Following staining with cationic dyes, local proteoglycan
depletion is observed in the cartilage matrix bordering
lesions [18]. Last, during end-stage OA, the hyaline car-
tilage is extensively eroded, and eburnated subchondral
bone is formed. In addition, osteophyte formation at the
joint margins can be observed [18, 19].
Recently, we revealed mRNA expression of the tran-
scription factor activating enhancer binding protein 2
epsilon (AP-2ε) in chondrocytes and during chondro-
genic differentiation of human mesenchymal stem cells.
Additionally, we detected AP-2ε in vivo in murinehypertrophic chondrocytes during embryogenesis and
in human articular cartilage via immunohistochemistry
[20, 21]. AP-2ε is a member of the AP-2 transcription
factor family, which consists of five isoforms (AP-2α to
AP-2ε) and influences a vast number of physiological
and pathogenic processes [22–24]. AP-2ε was also found
to be upregulated in articular cartilage of OA patients [21].
Furthermore, in vitro, AP-2ε induced the expression of
chemokine (C-X-C) motif ligand 1 (CXCL1) [25] and
inhibited COL2A1 (encoding collagen type II) in human
chondrocytic cells [26]. Despite these findings, adult mice
deficient for AP-2ε (Tfap2e−/−) do not show an obvious
cartilage phenotype under normal physiological conditions.
Therefore, in the present study, we analyzed possible
roles of AP-2ε in embryonic skeletal development, as
well as in articular cartilage function after the surgical
induction of OA, using the Tfap2e−/− mouse. The ob-
tained results will help to enhance understanding of the
functional role of AP-2ε in cartilage homeostasis in
health and disease, as well as knowledge of OA progres-
sion in general.
Methods
Transgenic mice, tissue preparation and animal studies
Tfap2e−/− mice were generated and kindly provided by
Markus Moser (Max Planck Institute for Biochemistry,
Munich, Germany). In those mice, a neomycin DNA con-
struct containing a stop codon was inserted into the sec-
ond exon of the Tfap2e gene between the ApaII and NotI
restriction sites (unpublished observations). This modifi-
cation leads to a premature termination of the translation
process of subsequent AP-2ε mRNA transcripts, resulting
in a complete absence of functional AP-2ε protein in ani-
mals homozygous for this genetic mutation.
Tfap2e−/− and the corresponding wild-type (WT) mice
were bred at 26 °C and 70 % relative humidity under a 12-
hour light/12-hour dark cycle at the University Hospital of
Regensburg, Germany. The mice were fed a breeding and
maintenance diet (Altromin Spezialfutter GmbH, Lage,
Germany) and given water ad libitum. The mice were ran-
domly housed in polypropylene cages with sawdust bed-
ding, and the cages were sanitized twice weekly. Animal
care and all experimental procedures were carried out in
accordance with guidelines under the German law govern-
ing animal care. The OA surgery was approved by the
Ethics Committee for Animal Research of the Bavarian
government. For all other experiments in which murine
tissue was used, it was sufficient to obtain supervision
from the local animal welfare officer (Dr Thilo Spruss,
University Hospital Regensburg) according to the German
Animal Welfare Act 2006 (article 4, using mice for scien-
tific purposes (including tissue, embryo and cell extrac-
tion) if no additional experimental procedures are carried
out with the animals). Therefore, except of the OA model,
Table 1 Primers used for genotyping of wild-type and Tfap2e
−/− micea
Primer Sequence (5′-3′)
mAP-2ε gen anti2 CTACGTCGCCCTGGACTTCGAGC
mAP2ε gen sense2 TGGAATCCTGTGGCATCCATGAAAC
pGK polyA down GGCTCTCCAGAACATCATCCCTGC
aSequences were obtained from M Moser
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tee for Animal Research of the Bavarian government was
necessary for the mouse studies.
All adult mice were killed after anesthetization by isoflur-
ane (2-chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane)
inhalation via cervical dislocation. Embryos were killed
by decapitation. To generate histological sections, tis-
sue and embryos were fixed for at least 3 days in
phosphate-buffered saline (PBS) containing 4 % para-
formaldehyde, decalcified in 20 % ethylenediaminetet-
raacetic acid (Sigma-Aldrich Chemie GmbH, Munich,
Germany) if necessary and embedded in paraffin. Sub-
sequently, 5-μm serial sections were cut. For genotyp-
ing, tail biopsies were used.
To obtain mouse embryos of a certain age, adult pu-
bescent mice were coupled overnight, and the weight of
the females was documented. At the desired time point,
the pregnant mice were killed after successful pregnancy
was determined on the basis of a clear weight increase.
Embryos were harvested by carefully opening the ab-
dominal wall and uterus.
To obtain adult articular cartilage of murine knee
joints, the joints were dissected and the cartilage layer of
the femoral condyles and the tibial plateau were carefully
separated from the underlying bone using sharp scissors
and a scalpel. Total RNA was isolated after pulverization
of the cartilage using liquid nitrogen and a mortar.
OA in 6- to 8-week-old WT and Tfap2e−/− mice was
induced by detaching the medial meniscus (DMM) from
the tibial plateau as described previously [27]. Briefly,
with the mice under general anesthesia using a 0.9 % so-
dium chloride solution containing 0.75 % ketamine and
0.16 % xylazine (10-μl intraperitoneal injection per gram
of body weight), the hind limbs were prepared for asep-
tic surgery. The right knee capsule was exposed follow-
ing a medial incision without transection of the patellar
ligament. Next, the medial meniscus was detached from
the tibial plateau using a fine cannula and a surgical
microscope. As a result, the meniscus translocated freely
into the joint space. Afterward, the skin was closed with
a metal clamp. During the procedure, close attention
was paid not to injure the articular cartilage surface. In
the left knee joint, the capsule was opened without fur-
ther treatment and served as a control (sham). The ani-
mals were killed 10 or 17 days after surgery, and the
knee joints were prepared for histological sectioning or
RNA isolation from articular cartilage. The progress of
OA was scored by stage and grade according to the scor-
ing system proposed by Pritzker et al. [18] using sections
stained with Safranin O/Fast Green and hematoxylin
and eosin, respectively. In a preliminary test, no signifi-
cant differences in OA development between male and
female mice could be observed. Thus, both sexes were
used in equal numbers.Preparation of genomic DNA and genotyping
Whole genomic DNA extracts were isolated from tail bi-
opsies as well as from hip cartilage explants using the
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) as
described by the manufacturer. The DNA concentration
and purity were measured using a NanoDrop device (Peq-
lab Biotechnologie GmbH, Erlangen, Germany). Tfap2e
genotyping was performed using a PTC-200 thermocycler
(MJ Research, Waltham, MA, USA). The following PCR
program was used: 5 minutes at 95 °C (initial denatur-
ation); 30 seconds at 95 °C (denaturation), 30 seconds at x
°C (annealing) (Table 1) and 30 seconds at 72 °C (elong-
ation), repeated 10 times, beginning with an annealing
temperature of 63 °C and 1 °C reduction per each subse-
quent cycle in a total volume of 50 μl containing 2 μl of
genomic DNA template, 1.5 μl of a mixture of three spe-
cific primers (20 μM; Sigma-Aldrich Chemie GmbH)
(Table 1), which bound to the Tfap2e genomic locus and
the neomycin insert, as well as 25 μl of FailSafe PCR 2×
PreMix D (Epicentre, Madison, WI, USA) and 0.5 μl of
Taq DNA polymerase (Roche Diagnostics GmbH, Mann-
heim, Germany). The initial PCR was followed by 30 add-
itional cycles of 30 seconds at 95 °C, 30 seconds at 53 °C
and 30 seconds at 72 °C. The PCR products were evalu-
ated by performing gel electrophoresis in a 1.5 % agarose
gel. Running the genomic DNA of homozygous Tfap2e−/−
mice on the gel resulted in a 300-bp band; DNA from
homozygous WT mice resulted in a 100-bp band; and
DNA of heterozygous animals produced both bands.
RNA isolation, reverse transcription and quantitative
real-time PCR
Total RNA of murine tissues was isolated using a
E.Z.N.A. MicroElute Total RNA Kit (Omega Bio-Tek,
Norcross, GA, USA) as described by the manufacturer.
The purity and concentration of the RNA were mea-
sured using a NanoDrop device (Peqlab Biotechnologie
GmbH), and cDNA was generated by reverse transcrip-
tion as described elsewhere [28]. Each reaction was per-
formed in a total volume of 20 μl containing at least 150
ng of total RNA.
Quantitative RT-PCR (qRT-PCR) was carried out using
the LightCycler 480 system from Roche Diagnostics GmbH.
Volumes of 1 μl of cDNA template, 0.5 μl of forward and
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(Roche Diagnostics GmbH) and 8 μl of water were com-
bined in a total volume of 20 μl. Primers were obtained
from Sigma-Aldrich Chemie GmbH and are listed in
Table 2. The following PCR program was used: 95 °C for
10 minutes (initial denaturation); 4.4 °C per second
temperature transition rate up to 95 °C for 10 seconds, x °C
for 10 seconds (annealing) and 72 °C for 20 seconds
(elongation), and y °C acquisition mode single, repeated
45 times (amplification). The annealing (x) and acquisi-
tion (y) temperatures were optimized for each primer
set. The PCR product was evaluated using melting curve
analysis, and each sample was analyzed at least in dupli-
cate. The expression level of the analyzed genes was
normalized to the expression level of the housekeeping
gene Actb (encoding β-actin).Table 2 Murine primer pairs used for quantitative real-time PCR
Gene Primer
Actb mβ-Act_885for
mβ-Act_1233rev
Acan mAggrecan_1922for
mAggrecan_2128rev
Col2a1 mColl2_2657for
mColl2_2918rev
Col10a1 mCol10_38for
mCol10_325rev
Mmp1a/Mmp1b mMMP1_17for
mMMP1_192rev
Mmp3 mMMP3_362for
mMMP3_466rev
Mmp13 mMMP13_899for
mMMP13_979rev
Tfap2a mAP-2α_1170for
mAP-2α_1238rev
Tfap2b mAP-2β_1355for
mAP-2β_1421rev
Tfap2c mAP-2γ_1115for
mAP-2γ_1651rev
Tfap2e mAP-2ε_388for
mAP-2ε_542rev
Timp1 mTIMP1_147for
mTIMP1_417rev
Timp2 mTIMP2_442for
mTIMP2_722rev
Timp3 mTIMP3_255for
mTIMP3_570revIn situ hybridization
For in situ hybridization of paraffin-embedded sections,
digoxigenin-labeled antisense RNA probes that were
specific for mouse Col2a1 (collagen, type II, alpha 1) and
Col10a1 (collagen, type X, alpha 1) mRNA transcripts
were generated using reverse transcription. The corre-
sponding vectors, which were kindly provided by Klaus
von der Mark (University of Erlangen-Nürnberg, Erlangen,
Germany), were linearized using EcoRI (for Col2a1) and
BamHI (for Col10a1) restriction enzymes, and the anti-
sense RNA probes were subsequently reverse-transcribed
using T3 RNA polymerase (for Col2a1) or T7 RNA poly-
merase (for Col10a1) with digoxigenin-labeled deoxynu-
cleoside triphosphates (Roche Diagnostics GmbH). Serial
sections of the hind limbs from WT and Tfap2e−/− em-
bryos were analyzed using in situ hybridization asProduct Sequence (5′-3′)
348 bp TGGAATCCTGTGGCATCCATGAAAC
TAAAACGCAGCTCAGTAACAGTCCG
206 bp CAGTTCACCTTCCAGGAAG
GTAGAGGTAGACCGTTCTCACG
261 bp CTACTGGAGTGACTGGTCCTAAGG
GGACCATCATCTCCAGGTTCTCC
287 bp CTGCCCCACGCATCTCCCAG
GCTTGCCTGGCGGTCCTGAG
175 bp CTGTTGCTTCTCTGGGCTGC
CTGCATTTGCCTCAGCTTTTC
104 bp GTTCCTGATGTTGGTGGCTTCAG
CTGTCTTGGCAAATCCGGTGTA
80 bp CCCAGCCCTATCCCTTGATGCCA
TGCAGGCGCCAGAAGAATCTGT
69 bp GCGGCCCAATCCTATCCT
CCATGGGAGATGAGGTTGAAG
67 bp AAAGCTGTCTCACGCACTTCAGT
AGCGCAGCGCAAATGG
537 bp ACCTAGCACGGGACTTCGCCT
GGGCGGGCGGGTTGTAACTG
154 bp GCCGACCCTGGGGAGCTACAC
CACCTCCGGCGCCGCTTAAA
270 bp AGACACACCAGAGCAGATACC
CCGGATATCTGCGGCATTTC
280 bp GCAGACGTAGTGATCAGAGCC
TCCCAGGGCACAATGAAGTC
315 bp GACCCTTGGCCACTTAGTCC
CGGATCACGATGTCGGAGTTG
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sue were detected using an anti-digoxigenin alkaline
phosphatase antibody and BM purple (both purchased
from Roche Diagnostics GmbH) according to the manu-
facturer’s instructions. The sections were mounted with
coverslips in Kaiser’s glycerol gelatin (Merck, Darmstadt,
Germany).
In vitro micromass cultivation of embryonic limb bud cells
Twelve to twenty-four limb buds that were derived from
littermates of pregnant homozygous mice were pooled
and dissolved in Dulbecco’s modified Eagle’s medium
(DMEM)/Ham’s F-12 (1:1) (PAA, Pasching, Austria) con-
taining dispase (1 U/ml) (Life Technologies, Carlsbad, CA,
USA), 10 % fetal calf serum (FCS; PAN Biotech GmbH,
Aidenbach, Germany), penicillin (100 U/ml; Sigma-Aldrich
Chemie GmbH) and streptomycin (10 μg/ml; Sigma-
Aldrich Chemie GmbH) at 37 °C for 30 minutes. Single
cells were collected by passaging through a 40-μm filter
and centrifugation at 280 × g for 4 minutes. Afterward, the
cells were resuspended in DMEM/Ham’s F-12 (1:1) con-
taining 10 % FCS and penicillin-streptomycin at a con-
centration of 20,000 cells/μl. Ten microliters of this
suspension were applied to each well of a 24-well plate,
which was then incubated for 3 hours at 37 °C and 5 %
CO2 for cell attachment. Subsequently, each well was
carefully flooded with 800 μl of DMEM/Ham’s F-12
(1:1) supplemented with 10 % FCS, penicillin-streptomycin,
L-ascorbic acid 2-phosphate (100 mM; Sigma-Aldrich
Chemie GmbH) and β-glycerophosphate (100 mM; Sigma-
Aldrich Chemie GmbH). The cultures were incubated for
up to 4 days, and the media were changed daily. Directly
after establishment (d0) and on each following day, the cells
of two wells were harvested for RNA isolation. Additionally,
on each day, a culture was stained with 1 % Alcian Blue
(Sigma-Aldrich Chemie GmbH) in 0.1 M HCl for 2 hours
after fixation with a solution containing 30 % EtOH,
0.37 % formaldehyde and 3.9 % acetic acid. After re-
moval of excessive Alcian Blue with PBS and 70 %
EtOH, the characteristic nodules that resembled chon-
drocytic differentiation became visible.
In vitro cultivation of articular cartilage explants
To obtain cartilage explants from the hip joints, the
pan-shaped articular cartilage that coated the femoral
head was carefully pulled off the underlying bone using
a fine forceps. From each mouse, two explants were iso-
lated, and their weights were determined. The explants
were cultured in 24-well plates at 37 °C and 5 % CO2 in
500 μl of DMEM/high glucose (PAA) containing 10 %
FCS (PAN Biotech GmbH), penicillin (100 U/ml; Sigma-
Aldrich Chemie GmbH), streptomycin (10 μg/ml; Sigma-
Aldrich Chemie GmbH) and amphotericin B (0.5 μg/ml;
Sigma-Aldrich Chemie GmbH). After 2 days, the mediumwas exchanged to serum-free medium (supplemented as
before), and a specific Mmp13 inhibitor (pyrimidine-4,6-
dicarboxylic acid, bis-(4-fluoro-3-methyl-benzylamide);
Merck) was added to a number of the explants at a con-
centration of 100 nM (one explant with and one without
inhibitor per mouse). After 4 days at 37 °C and 5 %
CO2, the supernatants were collected, and Mmp13 ac-
tivity and glycosaminoglycan (GAG) concentration were
measured. Additionally, genomic DNA of the remaining
explants was isolated, and their concentrations were
measured to indicate the number of chondrocytes in the
cartilage fragments. This value and the weight of the ex-
plants were used to normalize the absolute GAG con-
centration and Mmp13 activity in the supernatants.
Measurement of matrix metalloproteinase 13 activity and
glycosaminoglycan concentration in media
Analysis of Mmp13 activity in media was performed
using the SensoLyte 520 MMP-13 Assay Kit *Fluorimet-
ric* (AnaSpec, Fremont, CA, USA) according to the man-
ufacturer’s instructions. The fluorescence intensity, which
directly correlated with Mmp13 activity, was determined
using a FLUOstar Omega fluorescence reader (BMG LAB-
TECH, Ortenberg, Germany) at excitation/emission wave-
lengths of 485/520 nm.
For the detection of GAG, the WIESLAB sGAG quan-
titative kit was used (Euro-Diagnostica, Malmö, Sweden)
as suggested by the manufacturer. The color intensity,
which represented the GAG concentration, was measured
using a plate reader (MWG Biotech, Ebersberg, Germany)
at 650 nm.
Immunohistochemical staining of collagen cleavage
neoepitopes
Decalcified, paraffin-embedded sections of murine knee
joints were deparaffinized, rehydrated and incubated
with chondroitinase ABC (Sigma-Aldrich Chemie GmbH)
at 0.025 U/100 μl in 0.1 M Tris-HCl (pH 8.0) containing
60 mM sodium acetate and 0.02 % bovine serum albumin
for 90 minutes at 37 °C to remove GAG. Endogenous
peroxidase activity was quenched by treating the sec-
tions with 1 % H2O2 for 3 minutes. For the detection of
collagenase-induced generation of collagen type 2 neoe-
pitopes in the cartilage matrix, a rabbit antiserum raised
against the C1,2C (COL2 3/4Cshort) neoepitope was
used (IBEX Technologies, Montreal, QC, Canada). Sec-
tions were incubated with the primary antibody (1:100)
for 30 minutes at room temperature. After extensive
rinsing, the secondary antibody Histofine Simple Stain
MAX PO anti-rabbit (Nichirei Biosciences, Tokyo,
Japan) was incubated for 30 minutes at room temperature
and subsequently visualized using diaminobenzidine
chromogen (Dako, Hamburg, Germany). Finally, the tissue
was counterstained with hematoxylin. The specificity of
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cartilage as positive controls and sections without primary
antibody as negative controls.
Light and transmission electron microscopy
Light microscopy was performed using a Zeiss Axio-
vert200 microscope, which was equipped with an Axio-
Cam MRc camera (Carl Zeiss, Jena, Germany). AxioVs40
V 4.5.0.0 software (Carl Zeiss) was applied to quantify the
zones of gene expression after in situ hybridization, as well
as to measure skeletal parameters.
Transmission electron microscopy was conducted in
collaboration with Josef Schroeder and Heiko Siegmund
(University Hospital of Regensburg, Institute for Path-
ology, Regensburg, Germany). For this purpose, the fem-
ora and tibiae of 6- to 7-week-old WT and Tfap2e−/− mice
were isolated and chemically fixed for 16 hours in
Karnovsky’s reagent (2.5 % glutaraldehyde/1 % parafor-
maldehyde). Articular cartilage of the knee joint was
processed as described earlier [30, 31]. The transmission
electron micrographs were qualitatively evaluated by
Ernst B Hunziker. For this purpose, pictures derived
from equal articular cartilage zones were compared.
Statistical analysis
The results are expressed as the mean ± standard error
of the mean or as box-and-whisker plot with minimum
and maximum. Comparison between groups was made
using Student’s paired or unpaired t-test, and a P-value
<0.05 was considered statistically significant. All calcula-
tions were performed using GraphPad Prism software
(GraphPad Software, La Jolla, CA, USA).
Results
Tfap2e−/− mice exhibit only minor abnormalities in
cartilage and skeletal development during embryogenesis
AP-2ε expression was recently detected in human articular
cartilage and in hypertrophic chondrocytes of embryonic
day 14.5 (E14.5) WT mouse embryos [20, 21]. However,
adult Tfap2e−/− mice showed no obvious phenotype, and
the exact role of the transcription factor in cartilage devel-
opment and homeostasis was still unknown. Therefore, in
the first part of this study, we examined the embryonic de-
velopment of the Tfap2e−/− mouse for potential transient
abnormalities that might be compensated later and could
provide information about the influence of the transcrip-
tion factor on chondrogenesis.
We initially concentrated on E15.5 and E16.5, as these
stages are particularly suited to assessment of chondro-
cyte differentiation and endochondral ossification in the
murine limbs. For this purpose, heterozygous adult mice
were coupled overnight, and homozygous littermates
derived from the same female mouse were compared.
This ensured that all Tfap2e−/− and WT embryos wereof identical age and avoided unequal development due
to divergent mother animals. No significant differences
in total weight or size between the two genotypes could
be observed (Fig. 1a). Additionally, the hind limbs of the
embryos were embedded in paraffin, and sections were
stained for Col2a1 and Col10a1 mRNA expression via
in situ hybridization to more closely analyze limb devel-
opment (Fig. 1b). The expression zones of the two genes
were measured and normalized to the femur length. As
depicted in Fig. 1b, no significant differences between
the femora of WT and Tfap2e−/− specimens in total
length, Col2a1 expression zone or calcified region (bone)
could be observed. However, the Col10a1 expression zone
at E16.5 in Tfap2e−/− embryos was slightly but signifi-
cantly enhanced.
To define the impact of AP-2ε on earlier steps of em-
bryonic cartilage development, we used mesenchymal
cells isolated from limb buds of E11.5 WT and Tfap2e−/−
mouse embryos in high-density micromass cultures. The
production and accumulation of sulfated GAG was de-
termined by staining the cultures with Alcian Blue solu-
tion. Formation of the typical nodules could be observed
2 days after initiation of the cultures (Fig. 2a). Subse-
quently, the number and color intensity of the nodules
increased, but no definite discrepancy between the two
genotypes was observed. Additionally, the expression pat-
terns of prominent differentiation marker genes in cartilage
(aggrecan, Col2a1, Col10a1 and Mmp13) were compared
by qRT-PCR (Fig. 2b). No differences between Tfap2e−/−
and WT cells could be observed for aggrecan or Col2a1;
however, expression of Mmp13 and Col10a1 was increased
in Tfap2e−/− cultures in late stages of differentiation.
In sum, these data imply that AP-2ε most likely does
not play a major role during embryonic cartilage devel-
opment in mice. Alternatively, other factors may effect-
ively compensate for the loss of AP-2ε in the knockout
animals during embryogenesis. Nevertheless, the results
suggest that expression of the genes for Mmp13 and
Col10a1 could be affected by the loss of AP-2ε in differen-
tiated chondrocytes. To further support this hypothesis,
we expanded our investigation of the Tfap2e−/− mouse to
postnatal articular cartilage tissue in the second part of
this study.
Expression and activity of the proteinase matrix
metalloproteinase 13 is upregulated in articular cartilage
of Tfap2e−/− mice
Measuring the AP-2ε mRNA levels in articular chondro-
cytes of the knee joints of adult WT mice revealed a
strong induction in expression compared with the mes-
enchymal limb bud cells used for micromass differenti-
ation (Fig. 3a). This strongly hinted at a role of AP-2ε in
the homeostasis of articular cartilage and/or the regula-
tion of gene expression in this tissue type. However,
Fig. 1 Comparison of the embryonic skeletal development in embryonic days 15.5 and 16.5 wild-type and Tfap2e−/− mice. a The total weight and
size of 15.5- and 16.5-day-old (E15.5 and E16.5, respectively) wild-type (WT) and Tfap2e−/− embryos derived from three independent heterozygote
litters per time point were approximately identical. b In situ hybridization against collagen, type II, alpha 1 (Col10a1) and collagen, type X, alpha 1
(Col10a1) mRNA on the hind limbs of the embryos and subsequent measurement of the total femur length, the Col2a1 and Col10a1 expression
zones and the bone region was performed. The latter three were normalized to total femur length; the distal and proximal expression zones of
Col2a1 and Col10a1 were combined before normalization. A slight but significant increase in the Col10a1 expression zone could be observed in
the Tfap2e−/− fetuses at E16.5. Otherwise, no evidence for abnormal development in the Tfap2e−/− mice could be determined. The data are given
as the means ± standard error of the mean. ns, Not significant; Tfap2e−/−, Deficient for activating enhancer binding protein 2, epsilon. *P < 0.05.
Numbers indicate individual embryos used for each group
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age layer of 10.5-week-old Tfap2e−/− mice could be
determined at the histological or ultrastructural level
based on a qualitative analysis (Fig. 3b and c). To analyze
whether abnormal expression of another AP-2 isoform
might effectively compensate for the loss of AP-2ε in ar-
ticular cartilage of the knockout mice, expression of AP-2α, AP-2β and AP-2γ was determined, but no differ-
ences from WT animals could be measured (data not
shown). Next, we analyzed Mmp13 and Col10a1 expres-
sion, as these two genes showed differential expression
when we compared highly differentiated mesenchymal
cells of WT and Tfap2e−/− mice (see Fig. 2b). Interestingly,
in articular chondrocytes deficient for AP-2ε, expression
Fig. 2 Micromass in vitro differentiation of mesenchymal limb bud cells. Micromass cultures of mesenchymal cells isolated from the limb buds of
embryonic day 11.5 (E11.5) wild-type (WT) and Tfap2e−/− embryos were maintained for 4 days in vitro. a To compare the differentiation behavior
of WT and Tfap2e−/− cells, each day, a culture was treated with Alcian Blue solution to stain for secreted glycosaminoglycans. The nodules that
are characteristic for this assay became visible at the second day of the culture period. Their number, size and color intensity increased in both
genotypes by approximately the same amount. b Directly after initiation of the cultures (d0) and on each following day, mRNA expression of the
cartilage differentiation markers aggrecan, collagen, type II, alpha 1 (Col10a1) and collagen, type X, alpha 1 (Col10a1) and matrix metalloproteinase
(Mmp13) was analyzed by quantitative RT-PCR. A definite increase in the expression level of all four genes during the differentiation process was
detectable in cells of both genotypes. The expression of Col10a1 was enhanced, and expression of Mmp13 tended to be enhanced, at day 4 in
Tfap2e−/− cells compared with WT cells. The data are given as the means ± standard error of the mean. ns, Not significant; Tfap2e−/−, Deficient for
activating enhancer binding protein 2, epsilon. *P < 0.05. The assay was carried out four times with cells of four individual WT litters and three
times with cells of three individual Tfap2e−/− litters
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not the case for Col10a1 (Fig. 4a).
To evaluate the specificity of the detected Mmp13 dys-
regulation, expression of Mmp1 and Mmp3, two other
metalloproteinases that are known to play critical roles
in cartilage development and in human OA, was also ex-
amined [7, 15]. Two highly conserved genes for the inter-
stitial collagenase Mmp1, Mmp1a and Mmp1b, exist in
mice, but the mRNA of neither was detectable in articular
chondrocytes of WTand Tfap2e−/− mice (data not shown).Mmp3 was expressed, but no differences between the two
genotypes could be determined (Fig. 4a). In addition, no
differential expression of the genes for tissue inhibitors of
metalloproteinase 1, 2 and 3 (Timp1, Timp2 and Timp3,
respectively) was determined (Fig. 4b). Taken together, this
suggested that primarily Mmp13 is dysregulated in articu-
lar chondrocytes of Tfap2e−/− mice.
To provide evidence for enhanced catabolic activity in
articular cartilage tissue of Tfap2e−/− mice due to the ob-
served overexpression of Mmp13, we performed in vitro
Fig. 3 Activating enhancer binding protein 2, epsilon, expression in articular cartilage and analysis of the cartilage layer in wild-type and
Tfap2e−/− mice. a Activating enhancer binding protein 2, epsilon (AP-2ε) mRNA expression was measured in mesenchymal limb bud cells (LB)
of embryonic day 11.5 (E11.5) embryos and in articular chondrocytes (AC) from the knee joints of 10.5-week-old (10.5 w) mice via quantitative
RT-PCR. In the wild-type (WT) samples, a strong induction in the expression rate of the transcription factor was observed. As expected, when we
used genotype-specific primers, normal AP-2ε mRNA without the neomycin insert could not be detected in corresponding Tfap2e−/− samples,
serving as a negative control. b Histological sections through the knee joints of 10.5-week-old WT and Tfap2e−/− mice after staining with Safranin
O/Fast Green (left). Morphologically, no obvious abnormalities between the two genotypes could be detected at this age. Furthermore, the
thickness of the articular cartilage layer in the tibia and femur was similar in each genotype (right). c Exemplary pictures from the ultrastructural
analysis of the articular cartilage layer in the knee joints of adult WT and Tfap2e−/− mice depicting chondrocytes (left) and the extracellular matrix
(right). No obvious differences could be determined in a qualitative evaluation. The data are given as the means ± standard error of the mean. ns,
Not significant; Tfap2e−/−, Deficient for activating enhancer binding protein 2, epsilon. ***P < 0.001. In (A), cells of four individual litters were used
for LB and nine individual animals for AC. In (B), 14 WT and 15 Tfap2e−/− mice were compared. In (c), two mice were used for each genotype.
Micrographs shown are derived from the middle and deep zones of the cartilage layer and were adjusted to equal magnification
Fig. 4 Gene expression analysis in articular chondrocytes of wild-type and Tfap2e−/− mice. a The expression of collagen, type X, alpha 1 (Col10a1),
matrix metalloproteinase 13 (Mmp13) and Mmp3 was analyzed in the articular cartilage layer of knee joints of wild-type (WT) and Tfap2e−/− mice
(10.5 w) by quantitative RT-PCR. Mmp13, but not Col10a1 or Mmp3, was significantly overexpressed in Tfap2e−/− mice. b mRNA expression of
tissue inhibitor of metalloproteinase 1 (Timp1), Timp2 and Timp3 was analyzed in the articular cartilage samples, but no differences in the
expression rates of the three molecules could be detected when we compared WT and Tfap2e−/− animals. The data are given as the means ±
standard error of the mean. ns, Not significant; Tfap2e−/−, Deficient for activating enhancer binding protein 2, epsilon. **P < 0.01. Nine WT mice
and eight Tfap2e−/− mice were used for this experiment
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tion, Mmp13 activity in the supernatants was measured
using a fluorescence-based assay. We detected signifi-
cantly higher activity of the proteinase in medium derived
from explants deficient for AP-2ε relative to WT explants
(Fig. 5a, left). Furthermore, addition of a specific Mmp13
inhibitor resulted in a slight reduction of Mmp13 activity
in the WT and a significant reduction nearly to the WT
level in the Tfap2e−/− explants.
Additionally, the GAG content in the supernatants,
which is an indicator of proteoglycan and ECM degrad-
ation, was determined. Interestingly, the absolute GAG
concentration was also significantly higher in the superna-
tants of the Tfap2e−/− cartilage explants compared with
WT cartilage explants (Fig. 5b, left). Furthermore, the
Mmp13 inhibitor significantly reduced GAG release com-
pared with the untreated explants. Similar results were ob-
tained after normalization of the Mmp13 activity and the
GAG concentration to the weight of the explants before
cultivation, as well as to their DNA content, representingFig. 5 Enhanced matrix metalloproteinase 13 activity and matrix degradati
binding protein 2, epsilon. Articular cartilage of the femoral head of adult w
subjected to in vitro cultivation. Two days after establishment, a specific ma
explants. Another 3 days later, the supernatants were collected, and Mmp1
determined. Both were significantly enhanced in media from the Tfap2e−/−
Mmp13 inhibitor resulted in a significant reduction in Mmp13 activity and
supernatants of WT explants, albeit at a lower level. In addition, the absolu
(middle), as well as to the DNA content (right), of the corresponding expla
means ± standard error of the mean. ns, Not significant; Tfap2e−/−, Deficien
0.01; ***P < 0.001. Numbers indicate individual explants used for each grouthe number of cells in the cartilage fragments (Fig. 5a and
b, middle and right). In sum, these in vitro data strongly
support that expression and activity of Mmp13 is upregu-
lated in articular chondrocytes of Tfap2e−/− mice, result-
ing in enhanced matrix degradation.
Enhanced osteoarthritis development in Tfap2e−/− mice
To confirm this hypothesis in vivo, WTand Tfap2e−/− mice
were subjected to a model of OA. As we were unable to
observe any morphological or ultrastructural abnormalities
in the articular cartilage layer of 10.5-week-old Tfap2e−/−
mice under physiological conditions (see Fig. 3), we specu-
lated that potential abnormalities in the AP-2ε-knockout
mice become apparent under these conditions of stress. It
is also known, on the basis of studying other mouse models
deficient for cartilage-specific genes, that phenotypic varia-
tions sometimes become obvious only in pathological situ-
ations [27, 32–34].
OA was induced in the right hind limbs of 6- to 8-
week-old animals by DMM from the tibial plateau; theon in articular cartilage explants deficient for activating enhancer
ild-type (WT) and Tfap2e−/− mice (two per animal) was isolated and
trix metalloproteinase (Mmp13) inhibitor was added to a subset of the
3 activity (a) and glycosaminoglycan (GAG) concentrations (b) were
explants compared with the WT explants (left). Treatment with the
GAG release in the Tfap2e−/− explants. This was also detectable in the
te values for both parameters were normalized to the total wet weight
nts. Here, similar results were discovered. The data are given as the
t for activating enhancer binding protein 2, epsilon. *P < 0.05; **P <
p
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sion of OA was analyzed 10 and 17 days after surgery.
As depicted in Fig. 6a, animals of both genotypes exhib-
ited only minor signs of OA 10 days after disease onset.
Seventeen days after surgery, the WT mice showed mild
to moderate signs of OA, as expected on the basis of
previous studies [27] (Fig. 6a). These included wear, le-
sions and inhomogeneous staining near the cartilageFig. 6 Enhanced osteoarthritis progression in Tfap2e−/− mice. a In 6- to 8-w
induced in the right knee joint by detaching the medial meniscus (DMM).
(Sham). Ten days after surgery, all mice showed only minimal signs of OA. Sev
scores, whereas OA severity in Tfap2e−/− mice was significantly enhanced at t
after DMM surgery included wear, lesions and inhomogeneous staining (r
and featured no signs of OA (left). Slides of the top three rows were staine
the cartilage surface after staining with hematoxylin and eosin are shown
collagen cleavage neoepitope was performed to confirm matrix metallop
development of an OA-like phenotype in response to the DMM treatmen
detected in the DMM joints (arrowheads), whereas this was not the case i
Tfap2e−/− sections without primary antibody treatment (indicated by a “-”)
d Total RNA from the murine articular cartilage layer was isolated 10 and 1
binding protein 2, epsilon (AP-2ε) was analyzed in knee joints of WT mice
significant induction in the expression rate of the transcription factor coul
are given as box-and-whisker plots with minimum and maximum values i
significant; Tfap2e−/−, Deficient for activating enhancer binding protein 2,
animals per groupsurface (Fig. 6b). In striking contrast, both the severity
and the extent of the cartilaginous destruction were sig-
nificantly enhanced in Tfap2e−/− mice at the correspond-
ing juncture (Fig. 6a and b). In all of the sham joints, the
articular cartilage layer had a smooth surface contour
and manifested no signs of OA (Fig. 6b). To substantiate
that the DMM-treated joints exhibit an OA phenotype
and to confirm involvement of MMPs in this process,eek-old wild-type (WT) and Tfap2e−/− mice, osteoarthritis (OA) was
In the corresponding left knee joint, a control surgery was performed
enteen days after disease onset, WT mice exhibited low to moderate OA
his time point. b Visible damage to the articular cartilage tissue at day 17
ight, arrowheads). Cartilage of the sham joints had a smooth surface
d with Safranin O/Fast Green. In the bottom row, further examples of
. c Immunohistochemistry with an antiserum raised against the C1,2C
roteinase (MMP)-mediated extracellular matrix degradation and thus
t. Here, positive staining at the articular cartilage surface could be
n the sham joints. The specificity of the staining was controlled with
, and sections of human OA cartilage were used as positive controls.
7 days after OA induction, and expression of activating enhancer
10 and 17 days after OA onset relative to untreated WT knee joints. A
d be measured in the articular cartilage of the DMM joints. The data
n (a) and as the means ± standard errors of the mean in (d). ns, Not
epsilon. *P < 0.05; **P < 0.01; ***P < 0.001. Numbers indicate individual
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down products was performed using an antiserum against
the C1,2C cleavage neoepitope. A clear positive staining
signal was detectable at the surface of the articular
cartilage layer in the DMM joints of both WT and
Tfap2e−/− animals (Fig. 6c). In contrast, no staining
could be determined in the cartilage surface of the sham
joints. The specificity of the staining was controlled with
murine sections without primary antibody treatment
used as negative controls and sections of human OA
cartilage used as positive controls.
In addition to histology, we isolated RNA from the ar-
ticular cartilage of the knee joints of the mice in the OA
model. As detected in patients with OA compared with
healthy donors [21], a significant upregulation of AP-2ε
expression was measured in the joints subjected to OA
surgery compared with the untreated joints in WT mice
(Fig. 6d). Mmp1 was not detectable in murine articular
chondrocytes even after OA onset (data not shown). For
Mmp3, we also did not observe differential expression in
Tfap2e−/− mice compared with WT mice. Furthermore,
no significant changes in Mmp3 expression in the DMM
joints compared with the controls could be determined
at either time point (Fig. 7a). For Mmp13, again, a signifi-
cantly higher basal expression level in AP-2ε-deficient ar-
ticular chondrocytes could be detected when we compared
the sham joints of Tfap2e−/− mice with the sham joints of
WT mice at both time points (Fig. 7b). In addition, in both
genotypes, the expression of Mmp13 was significantly up-
regulated in articular cartilage derived from the DMM
joints compared with the sham controls 17 days afterFig. 7 Analysis of matrix metalloproteinase expression during osteoarthritis
10 and 17 days after osteoarthritis (OA) induction by detaching the medial
(Mmp3) (a) and Mmp13 (b) was analyzed by quantitative RT-PCR. (A) Mmp
at both time points, and only a minor induction could be detected in the
higher basal level of Mmp13 expression could be detected in the sham joi
wild-type (WT) mice at both time points. In addition, the expression of Mm
the sham joints 17 days after OA induction in both genotypes. In combina
increased total Mmp13 expression level in articular chondrocytes of the Tfa
means ± standard error of the mean. ns, Not significant; Tfap2e−/−, Deficient f
Five to eight animals were used for each groupdisease onset. This was expected owing to the pathological
conditions [13–15]. However, in combination with the
higher basal Mmp13 expression rate, this resulted in a sig-
nificantly increased total Mmp13 expression level at day 17
after OA onset in the Tfap2e−/− mice. This finding most
likely explains the enhanced OA manifestation observed in
these animals and shows that AP-2ε is involved in progres-
sion of the disease.
Discussion
Recently, we discovered physiological expression of the
transcription factor AP-2ε in hypertrophic chondrocytes
as well as in adult articular cartilage [20, 21]. Adult mice
deficient for AP-2ε, however, do not exhibit an apparent
cartilaginous or skeletal phenotype compared with WT
mice. Nevertheless, as observed in other murine knock-
out models of molecules important for cartilage develop-
ment, it could be possible that abnormalities arise only
in the embryo during chondrogenesis and are compen-
sated later in development via redundancy or irregular
cellular differentiation and proliferation. For instance,
mice with a cartilage-specific knockout of Mmp13 show
a significantly increased width of the hypertrophic zone
in the growth plate during embryonic and early postnatal
development [35]. This phenotype completely resolves at
approximately 12 weeks of age, and adult Mmp13−/− mice
display no phenotypic abnormalities [35]. Another example
for redundancy during chondrogenesis is the mouse defi-
cient for melanoma inhibitory activity/cartilage-derived,
retinoic acid–sensitive protein (MIA/CD-RAP), which also
does not manifest strong abnormalities [31]. Nevertheless,progression. Total RNA from the articular cartilage layer was isolated
meniscus (DMM), and expression of the matrix metalloproteinase 3
3 mRNA expression was approximately identical in all sham joints (S)
DMM joints compared with the sham joints. (b) In contrast, a significant
nts of the Tfap2e−/− mice compared with the sham joints of the
p13 was significantly upregulated in the DMM joints compared with
tion with the higher basal expression rate, this resulted in a significantly
p2e−/− mice at day 17 after OA onset. The data are given as the
or activating enhancer binding protein 2, epsilon. *P < 0.05; **P < 0.01.
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tion and delayed differentiation in MIA−/− mouse embryos
at E15.5/E16.5, resulting in abnormal growth plate archi-
tecture. This is compensated shortly afterward, however,
possibly via reduced cAMP response element-binding pro-
tein and activator protein 1 (AP-1) activity [36].
Thus, in the first part of this study, we compared the
embryonic skeletal development of Tfap2e−/− and WT
mice to find transient differences in chondrogenesis and
endochondral ossification, respectively. Those differences,
in turn, could provide valuable information about the in-
fluence of the transcription factor in these processes. Ad-
vanced stages of skeletal development (E15.5/E16.5) were
assessed in vivo via measurement of the embryos’ weight,
size and femoral lengths, as well as by determination of
the femoral expression zones of Col2a1 and Col10a1. In
addition, early chondrogenesis was monitored in vitro via
micromass cultivation of mesenchymal cells that were iso-
lated from limb buds of E11.5 WT and Tfap2e−/− mouse
embryos. Taken together, no fundamental abnormalities in
the embryonic development of Tfap2e−/− mice became ap-
parent in these experiments. However, at E16.5, a small,
albeit significant, increase in the Col10a1 expression
zone, which is specific for highly differentiated hyper-
trophic chondrocytes [37–39], was observed. Similarly,
the Col10a1 transcription rate was upregulated in AP-
2ε-deficient limb bud cells at very late stages of micro-
mass differentiation. Likewise, the expression of Mmp13
tended to be enhanced in those cells, which suggests
that loss of AP-2ε results in enhanced expression of
these hypertrophic markers [37, 39, 40]. Again, the ob-
served discrepancies were of rather low magnitude, and
no differences could be observed earlier during chon-
drogenesis, although the mRNA expression of AP-2ε
was clearly detectable in the mesenchymal cells. One
possible explanation for these findings is that the loss of
AP-2ε is compensated by an enhanced activity of redun-
dant factors. Here, other AP-2 isoforms expressed during
chondrogenesis come into consideration. For instance,
Huang et al. provided evidence that AP-2α is a negative
regulator of chondrocyte differentiation [41]. Likewise,
AP-2β expression was detected in the developing mouse
limb [42]. However, when AP-2ε is highly expressed in dif-
ferentiated chondrocytes, the compensatory mechanisms
may not be sufficient to fully negate the loss of the tran-
scription factor. Alternatively, it could also be possible that
AP-2ε does not impact gene expression in mesenchymal
cells and early chondroblasts, because of either a lack of
additional factors that are essential for AP-2ε function
or the general low level of expression of AP-2ε in these
cells. Regarding the latter, we determined a strong in-
duction of AP-2ε expression in articular cartilage tissue
isolated from adult mice compared with mesenchymal
limb buds in WT animals.We therefore concentrated on AP-2ε in adult joint
cartilage. The focus was on Col10a1 and Mmp13, as
these genes already showed differential expression during
late stages of in vitro differentiation of mesenchymal cells
of WT and Tfap2e−/− mice. Indeed, we found Mmp13
expression to be significantly upregulated in articular car-
tilage isolated form Tfap2e−/− mice compared with WT
animals, whereas Col10a1 was not deregulated. Although
we detected Col10a1 mRNA, the latter is most likely at-
tributable to the fact that expression of Col10a1 in
articular cartilage is restricted to single cells in the calci-
fied deep zone and thus is generally very low in this tis-
sue type [38, 43].
Mmp13 is known to be constitutively expressed in ar-
ticular cartilage at low levels during physiologic ECM
turnover [8, 14, 16, 17] and is capable of degrading na-
tive collagen type II [14, 44, 45] and aggrecan [46–48].
In addition, the family of matrix metalloproteinases com-
prises crucial mediators of cartilage destruction in OA. Of
those, MMP13 is the most important, being overexpressed
in the affected tissue of most patients with OA. Other var-
iants, such as MMP1 and MMP3, also were shown to play
a role in some cases of human OA [7, 13, 14, 19]. Further-
more, Mmp activity is strongly modulated at the posttran-
scriptional level via catalytic processing and Timp1, Timp
2 and Timp 3 [45]. Expression of the latter was unchanged
in Tfap2e−/− mice, revealing that Timps do not counter-
balance the enhanced Mmp13 mRNA expression [49, 50].
Furthermore, Mmp13 activity was directly measured
in supernatants of articular cartilage explants and was
indeed significantly enhanced in Tfap2e−/− mice. To deter-
mine the functional correlation, GAG release was assessed,
which we found to be significantly higher in media from
AP-2ε-deficient explants. A specific Mmp13 inhibitor
confirmed that Mmp13 was mainly responsible for these
observations because, after addition of the compound,
the prior significant difference between the two geno-
types was abolished.
Unexpectedly, in vivo the articular cartilage tissue of
untreated 10.5-week-old Tfap2e−/− mice exhibited no
evident abnormalities. In striking contrast, profound dif-
ferences compared with WT mice became obvious after
OA induction via DMM surgery. In one of our previous
studies, the same OA model was carried out with MIA/
CD-RAP deficient mice of a similar age. Here, slight
signs of OA were detectable 10 days after surgery, and
moderate signs were detectable 21 days after surgery
[27]. Accordingly, comparable OA development could
be observed in this study after 10 and 17 days. Again, in
this model, a significantly higher basal level of Mmp13
expression in AP-2ε-deficient articular chondrocytes could
be confirmed when we compared the sham joints of both
genotypes. This, in combination with the characteristic
OA-dependent induction of Mmp13 expression, resulted
Fig. 8 Graphical illustration of the results. Our data suggest that
the loss of activating enhancer binding protein 2 epsilon (AP-2ε)
results in an enhanced basal matrix metalloproteinase 13 (Mmp13)
expression level in articular chondrocytes of Tfap2e−/− mice as
compared with wild-type (WT) mice. After osteoarthritis (OA)
onset, expression of Mmp13 is induced in both genotypes by a
comparable amount (3.2-fold in WT mice and 2.4-fold in Tfap2e−/−
mice), which is most likely due to the effect of other OA-associated
transcription factors. However, because of the higher basal expression
level, a similar induction rate leads to a significantly higher Mmp13
expression level in chondrocytes of Tfap2e−/− mice compared with
WT mice 17 days after OA surgery. Tfap2e−/−, Deficient for activating
enhancer binding protein 2, epsilon
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in the Tfap2e−/− mice at day 17 after disease onset, which
most likely is responsible for enhanced OA severity in
these animals. Other examples of genetically manipulated
mice that were deficient for cartilage-associated molecules
and did not exhibit phenotypic alterations in the adult
stage, but nevertheless responded to pathologic conditions
or tissue stress differently from the WT mice, including
mice deficient for Adamts5 (a disintegrin and metallopro-
teinase with thrombospondin motifs 5), MIA/CD-RAP
and Mmp13 [27, 32–34]. In indirect correlation with our
results, OA severity was significantly reduced in the latter
mice. Further analyses in Mmp13 transgenic mice re-
vealed that a constant overexpression of Mmp13 in
articular chondrocytes could indeed promote disease
progression [51], thus confirming that a dysregulation
of Mmp13, as observed in the Tfap2e−/− mouse, strongly
influences OA development.
In summary, the obtained data suggest that AP-2ε
effectively represses basal Mmp13 expression under nor-
mal, non-OA conditions in articular chondrocytes of
WT mice and that this control mechanism is lost in
Tfap2e−/− animals. However, despite this inhibitory ef-
fect, an induction of Mmp13 expression after OA onset
could be measured not only in Tfap2e−/− mice but also
in WT animals. It is known that changes in the gene ex-
pression profile of the affected chondrocytes take place
during OA, including upregulation of factors that drive
expression of various effector molecules such as Mmps.
For example, Mmp13 expression was shown to be up-
regulated by Runx2 (runt-related transcription factor 2),
AP-1, HIF-2α (hypoxia-inducible factor 2, alpha) and Ets
(E26 transformation-specific) family members [52–56].
As Mmp13 expression is similarly induced in both geno-
types after OA onset (about 3.2-fold in WT mice and
2.4-fold in Tfap2e−/− mice), the inhibitory effect of AP-
2ε on Mmp13 in the WT animals must be overbalanced
by one or more of these activating factors. However, owing
to the significantly higher basal expression, the induction
results in a significantly higher Mmp13 expression level in
articular chondrocytes of Tfap2e−/− mice compared with
WT mice also at day 17 after OA surgery (Fig. 8). As
demonstrated in the OA model, this increases the sus-
ceptibility of the cartilage tissue to destruction after
joint overload, resulting in enhanced OA severity in the
AP-2ε-deficient animals.
As determined in vitro, the higher basal expression
and activity of Mmp13 in articular chondrocytes of
Tfap2e−/− mice shifts physiologic matrix turnover to the
catabolic side also under non-OA conditions. Hence, it
is possible that Tfap2e−/− mice develop OA-like symp-
toms with advanced age. In Mmp13 transgenic mice that
strongly overexpress Mmp13 in articular chondrocytes,
cartilage destruction was apparent at 5 months of age.However, it could also be possible that the loss of AP-2ε
is compensated in the Tfap2e−/− animals via unknown
mechanisms later during development. For this study, all
experiments were carried out with mice up to 12 weeks
of age, and further investigations with older mice of 6 to
12 months of age will be very interesting.
The expression of AP-2ε was induced in joints sub-
jected to OA surgery compared with untreated joints in
WT mice, which was similarly observed in humans [21].
This induction may constitute an attempt of chondro-
cytes to prevent the activation of Mmp13 after initial
OA onset. However, at the same time, other regulatory
factors drive the expression of Mmp13 and eventually
predominate over AP-2ε. Thus, the increase of AP-2ε
expression might only be sufficient to delay OA progres-
sion, but not to fully prevent cartilage destruction, which
is in line with our observations in the OA model.
Conclusions
Despite the publication of large numbers of scientific re-
ports, numerous aspects of cartilage development, destruc-
tion and regeneration are still not fully understood. Hence,
studies introducing new players or interactions influencing
these complex processes are of great importance. In this
Niebler et al. Arthritis Research & Therapy  (2015) 17:119 Page 15 of 16work, we reveal a novel role of the transcription factor
AP-2ε in the control of articular chondrocyte gene ex-
pression and OA development by influencing Mmp13
expression and activity in vivo. Thus, this finding adds
to the understanding of regulatory mechanisms under-
lying OA and might influence the development of future
treatment options.
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